1-8 of 8
Sridhar Ramaswamy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A091: Targeting homologous recombination repair defects in lung cancer

Asli Muvaffak, Yinghui Zhou, Bin Feng, Sarah Wang, Jing Ju Wang, Sridhar Ramaswamy, Kevin G Coleman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A091.
https://doi.org/10.1158/1535-7163.TARG-19-A091
Published: 01 December 2019
View article titled, Abstract A091: Targeting homologous recombination repair defects in lung cancer
Journal Articles

TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo

Srimoyee Ghosh, Geeta Sharma, Jon Travers, Sujatha Kumar, Justin Choi, H. Toni Jun, Marilyn Kehry, Sridhar Ramaswamy, David Jenkins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 632–641.
https://doi.org/10.1158/1535-7163.MCT-18-0836
Published: 01 March 2019
View article titled, TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth

Cleidson P. Alves, Ipsita Dey-Guha, Sheheryar Kabraji, Albert C. Yeh, Nilesh P. Talele, Xavier Solé, Joeeta Chowdhury, Mari Mino-Kenudson, Massimo Loda, Dennis Sgroi, Anne-Lise Borresen-Dale, Hege G. Russnes, Kenneth N. Ross, Sridhar Ramaswamy
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (1): 254–263.
https://doi.org/10.1158/1535-7163.MCT-16-0868
Published: 01 January 2018
View article titled, AKT1<sup>low</sup> Quiescent Cancer Cells Promote Solid Tumor Growth
Open the PDF for AKT1<sup>low</sup> Quiescent Cancer Cells Promote Solid Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Abstract A102: A comparative pharmacokinetic-pharmacodynamic-treatment study of PARP inhibitors demonstrates favorable properties for niraparib activity in preclinical tumor models

Kaiming Sun, Grace Poon, Sarah Wang, Paul Vancutsem, Sridhar Ramaswamy, Jeffrey Hanke, Jing Yu Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A102.
https://doi.org/10.1158/1535-7163.TARG-17-A102
Published: 01 January 2018
View article titled, Abstract A102: A comparative pharmacokinetic-pharmacodynamic-treatment study of PARP inhibitors demonstrates favorable properties for niraparib activity in preclinical tumor models
Journal Articles

Abstract B013: Elevation of immune cell infiltration and interferon-stimulated gene expression is associated with niraparib treatment in murine syngeneic tumor models

Sarah Wang, Kaiming Sun, Yonghong Xiao, Keith Mikule, Sridhar Ramaswamy, Jeffrey Hanke, Jing Yu Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B013.
https://doi.org/10.1158/1535-7163.TARG-17-B013
Published: 01 January 2018
View article titled, Abstract B013: Elevation of immune cell infiltration and interferon-stimulated gene expression is associated with niraparib treatment in murine syngeneic tumor models
Journal Articles

AKT Inhibition Promotes Nonautonomous Cancer Cell Survival

Salony, Xavier Solé, Cleidson P. Alves, Ipsita Dey-Guha, Laila Ritsma, Myriam Boukhali, Ju H. Lee, Joeeta Chowdhury, Kenneth N. Ross, Wilhelm Haas, Shobha Vasudevan, Sridhar Ramaswamy
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (1): 142–153.
https://doi.org/10.1158/1535-7163.MCT-15-0414
Published: 07 January 2016
View article titled, AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Open the PDF for AKT Inhibition Promotes Nonautonomous Cancer Cell Survival in another window
Includes: Supplementary data
Journal Articles

Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Erin M. Coffee, Anthony C. Faber, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C263.
https://doi.org/10.1158/1535-7163.TARG-13-C263
Published: 01 November 2013
View article titled, Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Journal Articles

Analysis of the 70-gene breast cancer prognosis signature in a general hospital population.

Ben Wittner, Dennis Sgroi, Paula Ryan, Tako Bruinsma, Annuska Glas, Anitha Male, Sonika Dahiya, Karleen Habin, Rene Bernards, Daniel Haber, Laura van 't Veer, Sridhar Ramaswamy
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B174.
Published: 01 November 2007
View article titled, Analysis of the 70-gene breast cancer prognosis signature in a general hospital population.